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1. Introduction 
Membranes fulfill the essential need of all living species to separate different compartments. 
On the other hand, in a cell the homeostatic environment can only be maintained by the 
cellular membrane acting as a selective ‘filter’, which allows the cell to continuously 
communicate with other cells. Mechanisms which facilitate the translocation of materials 
across the membrane regulate the entrance and disposal of ions, amino acids, nutrients, and 
signaling molecules. 
This selective transport across cellular membranes is carried out by two broad classes of 
specialized proteins, which are associated with or embedded in those lipid bilayers: 
channels and transmembrane transporters. They work by different mechanisms: Whereas 
channels catalyze the passage of ions (or water and gas in the case of the aquaporin channel) 
(Agre, 2006) across the membrane through a watery pore spanning the membrane-
embedded protein, transporters are working via a cycle of conformational changes that 
expose substrate-binding sites alternately to the two sides of the membrane (Theobald & 
Miller, 2010). 
If we regard the force that drives the transport process there is also a huge difference in the 
way ion channels and transporters act. Channels assist a downhill movement along a 
concentration gradient (passive diffusion), whereas in transporters it is usually directed 
against a concentration gradient of the substrate. Thus, in order to comply with their 
business, transporters are dependent on another source of the cellular energy. Secondary 
active transporters rely on ionic gradients. In the case of primary active transporters ATP is 
the driving force (Wang et al., 2010). 
A comprehensive list of all annotated transport proteins is freely available online on the 
TCDB website (http://www.tcdb.org). This Transporter Classification Database uses an 
International Union of Biochemistry and Molecular Biology (IUBMB) approved system of 
nomenclature for transport protein classification. The TC system is analogous to the Enzyme 
Commission (EC) system for classification of enzymes, except that it incorporates both 
functional and phylogenetic information (Saier et al., 2006; Saier et al., 2009). 
According to the TCDB system Membrane Transport proteins can be classified as follows 
(List of families and subfamilies of the TC system): 
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1. Pores and channels 
a. Helical channels 
b. Strand porins 
c. Pore-forming toxins 
d. Non-ribosomally synthesized channels 
e. Holins 
2. Electrochemical-potential-driven transporters 
a. Transporters or carriers (uniporters, symporters and antiporters) 
b. Non-ribosomally synthesized transporters 
3. Primary active transporters 
a. P-P-bond-hydrolysis-driven transporters 
b. Decarboxylation-driven transporters 
c. Methyl-transfer-driven transporters 
d. Oxidoreduction-driven transporters 
e. Light-driven transporters 
4. Group translocators 
5. Transmembrane electron carriers 
6. Accessory factors involved in transport 
7. Incompletely characterized transport systems 
Our special interest focuses on transmembrane transport proteins (‘transporters’). Excellent 
manuscripts on membrane channels have been provided by other groups (Gumbart et al., 
2005; Schmidt et al., 2006). 
To date more than 400 membrane proteins have been annotated in the human genome. Two 
major superfamilies - which are also intensively investigated in our group - are the  
ATP- binding cassette transporters (ABC, e.g. P-glycoprotein), and the solute carrier 
superfamily (SLC). They will be discussed into more detail in section 3 of this chapter. 
1.1 Transporters as pharmacological targets 
Transport proteins are playing important roles in the whole drug discovery and development 
process. They regulate absorption, distribution, and excretion of drugs and therefore influence 
drug disposition, therapeutic efficacy and adverse drug reactions in the human body. This has 
to be taken into account in pharmacological studies (Giacomini et al., 2010). 
It is estimated that transporters account for about 50% of drug targets. However, their 
modes of (selective) transport are only poorly understood. This is due to difficulties in 
membrane protein purification, expression, and crystallization (Caffrey, 2003), which is still 
in its childhood. As a consequence there exists a striking disproportion between the number 
of entries of resolved structures of soluble proteins and membrane proteins in the protein 
databank (PDB, http://www.pdb.org/). To date, only about 2% (1462 by Sept 2011) of the 
structures are from transmembrane proteins (75594 structures in total). Out of these there 
are only 302 unique structures (proteins of same type but from different species are 
included) (Irvine). Moreover, a significant number of the membrane protein structures 
determined are at relatively low resolutions (Lindahl & Sansom, 2008). 
However, there are tremendous efforts as to ameliorate the methods in order to obtain 
atomic resolution structures of membrane protein molecules (Newby et al., 2009). Thus, for 
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the past two decades, the number of available structures of membrane proteins has been 
climbing the exponential foot of the growth curve, since it is doubling every three years 
(Theobald & Miller, 2010). 
For a medicinal chemist, the availability of a growing number of structures, paves the way 
for further in silico studies. Some are very promising in a way that they can be used as 
templates in order to build up a homology model of the membrane protein of interest. Those 
models, which may further be applied for Molecular Dynamics (MD) Simulation and 
Docking Studies, give us the opportunity to gather new insights into the molecular structure 
and function of the protein under investigation and the behaviour of certain ligands in the 
binding site. 
As translocation always involves a dynamic process, which cannot easily be studied by 
mere experimental techniques, above all, the application of long-term MD simulations 
should be implemented into the whole process of drug discovery and development. Due to 
significant increase in computational power and improvements in parallelization 
techniques, nowadays simulations of membrane transport proteins may stretch up to 
microseconds - that is, to physiologically relevant time scales. In this review we are 
describing the theory and methodology related to computational techniques used in the 
modeling of transporters and we will outline the recent developments in the field of ABC 
transporters and neurotransmitter transporters. 
2. Methods 
2.1 Homology modeling 
2.1.1 Basic concepts 
Despite the enormous increase of published structural data for proteins, the particular 
availability for a protein of interest can vary from the sheer presence of the amino acid 
sequence to a multitude of high-resolution X-ray structures. Fortunately, Mother Nature 
was not too generous in providing unique structural folds for functionally related proteins, 
as the structural arrangement within a family of homologous proteins is much higher 
conserved than the respective amino acid sequences (Lesk & Chothia, 1980). Thus, in many 
cases the combination of a primary sequence on the one hand and one or more reasonably 
well-resolved homologue structures on the other hand can result in homology models 
surprisingly well representing the molecular reality, paving the way to successful 
comparative modeling studies. The process of predicting the 3D structure of a protein can be 
achieved by four main steps: fold assignment, target-template sequence alignment, building 
and evaluation of the models (Cavasotto, 2011).  
2.1.2 Assignment of the basic fold and sequence alignment 
The first step towards a good model is the identification and careful selection of structurally 
related template proteins. Although generally a high percentage of global sequence identity 
is a good indicator for the model quality to be expected, it must be kept in mind that the 
identity in the area of interest, i.e. the binding site(s), can differ significantly from overall 
values. One should strive to put the main focus during template selection on facilitating a 
maximum of accuracy in modeling those vital regions. 
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Maybe the best source for structural templates is the Protein Data Bank (Berman et al., 2000). 
As mentioned earlier, it offers the coordinates of structurally resolved proteins, including 
large amounts of surplus information like primary sequence, experimental settings or co-
bound ligands and ions. Search tools like BLAST and FASTA (Altschul et al., 1997; Pearson, 
1990) usually do reasonably well in identifying the correct fold of a protein. The second, 
even trickier step is the subsequent alignment step of target and template sequence, as it is 
possible with T-Coffee or CLUSTAL W (Notredame et al., 2000; Thompson et al., 1994). 
Conserved residues and regions of experimentally determined proximity need to be aligned 
as accurately as possible. Multiple alignments of sequences belonging to the same gene 
family can significantly enhance the performance of the search for conserved residues or 
even regions, but thorough literature search and manual adjustment of the alignment are 
inevitable in order to achieve best results. 
A good example for the importance of taking a comprehensive look at the research subject is 
the meanwhile annual GPCR Dock competition (Kufareva et al., 2011), where prior to the 
release of newly resolved G-Protein Coupled Receptors (GPCR) 3D structures, modeling 
groups get the chance to submit their best efforts of predicting the correct receptor and 
ligand conformation. It turned out, that advanced modeling tools and human intervention 
contributed about equally to the success of the individual approaches.  
2.1.3 Building and refinement of the models 
Once it is assumed that the alignment meets all available experimental data, it can be started 
to calculate coordinates for the target residues. Although automated homology modeling 
methods exist, the yielded models tend to lack accuracy, especially in cases of low sequence 
identity (Dalton & Jackson, 2007). 
Usually, the crude model is built by aligning the basic backbone framework, the so-called 
structurally conserved regions (SCRs). Conserved secondary structural elements like α-
helices or β-sheets are inherited, being responsible for the general shape of the model. 
Several homology modeling approaches also try to include information about known 
ligands into the binding site construction in order to meet its particular geometry (Evers & 
Klebe, 2004; Sherman et al., 2006). 
Subsequently, assignment of the side chain conformations needs to be done according to 
steric and energetic constraints. Identical residues usually can be considered to be oriented 
similarly, likewise highly similar amino acids. For non related residues, rotamer libraries 
can provide initial geometrical guesses (Schrauber et al., 1993), although other effects like 
packing energies may lead to significant deviations. Up to 30% of side chain conformations 
in X-ray structures do not correspond to usual rotamers, yet adopting energetically allowed 
conformations. Naturally, selecting the most probable side chain orientation solely 
according to statistical criteria is problematic, so methods including structural features of 
the local environment have been developed (Deane & Blundell, 2001). Still, some cases 
require manual adjustment, for instance the incorporation of known disulfide bridges, 
specific internal hydrogen bonds or ion binding pockets. 
The major challenge in comparative modeling is the treatment of structurally variable 
regions (SVRs). Especially flexible loop regions lacking a structural template are difficult to 
predict, since the calculation time increases nearly exponentially with the degrees of 
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freedom added by every flexible residue. There are several strategies to meet this issue. 
Knowledge-based strategies try to find structural guesses by automated database search for 
related sequence sections in other proteins, possibly not even close to being genetically 
similar. From a computational point of view, conformational searches by ab initio calculation 
of the desired region are more costly, but recent approaches yielded reasonably good results 
for a loop length up to 17 residues (Mehler et al., 2002; Zhao et al., 2011). For significantly 
longer loops, in case that the problematic region is remote from the actual binding site(s) 
and not considered being directly linked to the binding process, it can be viable to leave it 
up to the standard modeling software how to build the respective flexible region, and hope 
for subsequent MD simulations to find a near-to-native conformation (Amaro & Li, 2010). 
The model building process bears numerous sources of unfavorable steric strain energies, 
calling for an appropriate minimization procedure. As one can imagine, this step has to be 
carefully balanced in order to overcome steric clashes without compromising tediously 
elaborated side chain orientations or, even worse, entire conserved regions. Instead of global 
optimization attempts good minimization protocols start with local treatment of clashes 
with initially fixed backbone atoms. Thus, solvent molecules, ions and hydrogen atoms 
possibly responsible for large initial forces can adopt energetically more favorable positions. 
Gradually, initial tethering forces are reduced, avoiding artificial distortions (Höltje et al., 
2008). This can be facilitated by molecular mechanics calculations using different force fields 
like CHARMM (Brooks et al., 1983), OPLS (Jorgensen & Rives, 1988) or AMBER (Weiner et 
al., 1984). In contrast to force fields for small molecules, they have to handle huge systems, 
therefore being usually somehow simplified regarding the treatment of long-distance non-
bonding interactions or non-polar hydrogen atoms, called united-atom models. 
Energy minimized models may be further optimized by molecular dynamics (MD) 
simulations, as reported in-depth in section 2.3. 
2.1.4 Model evaluation 
Predictions including as many degrees of freedom as homology models desperately need 
reliable tools to estimate their quality, as the accuracy of a 3D model is responsible for the 
amount of information that can be gained by it (Marti-Renom et al., 2000). Several 
evaluation programs exist; many of them are available online on server-basis. The SWISS-
MODEL (Arnold et al., 2006) (http://swissmodel.expasy.org) and the SAVES server 
(http://nihserver.mbi.ucla.edu/SAVES), for instance, offer a variety of local and global 
quality estimation tools (Benkert et al., 2011; Hutchinson & Thornton, 1996; Zhou & Zhou, 
2002). It is important to look at both, as they are not necessarily mutually related. 
A comprehensive stereochemistry check can be carried out using the Procheck suite 
(Laskowski et al., 1993), searching for geometrically unusual residues in a given protein 
structure by comparison with stereochemical parameters of high-quality benchmark 
structures. Likewise, the What_Check module of the WHATIF package and the VADAR 
web server do a similar job (Vriend, 1990; Willard et al., 2003). The features examined 
include the planarity of aromatic ring system and peptide bonds, bond lengths and basic 
checks like Cα-chirality. 
Once the yielded quality statistics are acceptable within the limitations of the possible, a 
model can be considered ready for the further use in, for instance, docking studies. 
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2.2 Molecular docking 
Molecular Docking is a versatile tool in structure based drug design. This technique is able 
to predict possible orientations of one molecule to another. In this section we will focus on 
protein-ligand docking, describing the interaction of a small molecule in a binding pocket of 
the protein of interest. 
In principle molecular docking is comprised of three consecutive steps: i) the definition of 
the binding site, ii) the placement of the ligand inside the defined site, and iii) the ensuing 
evaluation of this placement, called scoring. 
2.2.1 Binding site identification 
The right determination of the binding site of the ligand is essential for the subsequent 
docking process. If the active site is not known there are several algorithms that are able to 
detect potential binding pockets (extensively reviewed in (Henrich et al., 2010)). These 
programs scan the protein surface for cavities that fulfill certain geometrical constraints, 
which mark them as possible ligand binding sites. While the program LIGSITE uses a grid 
for the surface scan (Hendlich et al., 1997), the PASS algorithm utilizes layers of spheres that 
should describe buried cavities (Stouten & Brady, 2000). 
In order to consider also physico-chemical criteria in binding site detection the surface of the 
protein can be scanned with fragments of ligands with subsequent calculation of their 
complementarity. Another approach to get an idea about potential active sites can be 
achieved by comparing the query protein with homologues, as proteins with related 
function share similar binding sites. For this purpose the program CAVBASE (Kuhn et al., 
2007), which relies on the LIGSITE algorithm, has been developed. 
As soon as the binding site is known, it has to be characterized in order to get information 
about specific binding possibilities through non-covalent interactions. To detect these hot 
spots atom probes, ligand fragments or whole small molecules are positioned inside the 
binding pocket. The program GRID is able to detect interactions and solvation effects by 
calculating the interaction energy between grid points of the binding pocket and certain 
atom probes (Reynolds et al., 1989). On the other hand, the multiple copy simultaneous 
search (MCSS) method places thousands of probe copies inside the pocket. After energy 
minimization those probes cluster at certain local minima defining the hot spots (Caflisch et 
al., 1993). 
2.2.2 Search algorithms 
The role of the search algorithm is the correct placement of the ligand in the binding pocket. 
Ideally it should therefore consider all possible degrees of freedom, which leads to higher 
accuracy. However, due to limitations regarding computer power, this is penalized in favor 
of higher speed by reducing the number of the degrees of freedom (Sousa et al., 2006). 
Although in protein-protein docking the rigid-body approximation is still applied (Kuntz et 
al., 1982), in protein-ligand docking the small molecule is treated flexible.   
Approaches that try to explore all degrees of freedom of the ligand systematically comprise 
conformational search methods, fragmentation methods or database methods. By applying 
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conformational search methods, every rotatable bond of the ligand is rotated in fixed 
increments. As this can easily lead to a combinatorial explosion, this technique can only be 
applied for small or rigid ligands. More prevalently used are the so-called fragmentation 
methods that place fragments of the ligand in the binding pocket, which are subsequently 
fused. Depending on the fragmentation and placing of the ligand place and join and 
incremental approaches can be distinguished. Popular docking programs utilizing this type of 
search algorithms include LUDI (Bohm, 1992), FlexX (Rarey et al., 1996), DOCK (Ewing et 
al., 2001), ADAM (Mizutani et al., 1994) or Hammerhead (Welch et al., 1996).  
A computationally efficient way to search for possible orientations forms the database 
method. For this protocol a conformational library of the ligand is prepared which is docked 
rigidly into the binding site. 
Besides systematic search algorithms there are programs that prefer stochastic principles 
for binding mode prediction. At this the flexibility of the ligand is provided by random 
conformational changes that are either kept or rejected on basis of a direct evaluation of 
the conformation. Among others genetic algorithms present a convenient tool for this 
purpose.  With this optimizing procedure a random population of possible ligand poses is 
generated, where the characteristics (degrees of freedom) of each are stored in its genetic 
code (chromosome). By applying genetic operations, like cross-over or mutation, new 
poses are generated and subsequently scored. Depending on this fitness score the pose is 
either rejected or it replaces the least fit member of the population. This procedure is 
conducted over thousands of cycles which ends up in highly optimized ligand 
orientations. This protocol is included in the popular docking programs GOLD (Jones et 
al., 1995; Verdonk et al., 2003) and AUTODOCK (Goodsell et al., 1996; Goodsell & Olson, 
1990; Olson et al., 1998).  
Another possibility to consider ligand flexibility is presented by molecular dynamics 
simulation of the ligand in the binding pocket. However, this is mainly used in combination 
with other search algorithms (Kitchen et al., 2004). 
In the last years not only the flexibility of the ligand but also protein movements due to 
ligand binding gained more and more importance (B-Rao et al., 2009; Cozzini et al., 2008). 
Although it is known that some proteins undergo large structural changes, even domain 
rearrangements, upon ligand binding, by now it is not possible to cover that in reasonable 
time and effort. However, since docking a ligand into the right conformation of the binding 
site is extremely important for the quality of the resulting orientations, efficient 
workarounds have been developed. Soft docking is one possibility to account small 
movements of the protein side chains during docking (Jiang & Kim, 1991). For this 
technique soft potentials are applied on certain side chain atoms in the binding pocket, 
which therefore tolerate overlap with ligand atoms. The merit of this technique is the easy 
implementation, as only scoring parameters have to be adapted. On the other hand only 
small changes can be considered and there might be a bias towards the starting structure.  
With the help of rotamer libraries, movements of side chains are included in the search 
algorithm (Leach, 1994). Depending on the size of the library this method calls on moderate 
computational power and is able to adapt to certain ligand conformations. Nevertheless, as 
the backbone is kept rigid large structural movements cannot be covered. 
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Docking into multiple protein structures (MPS) is therefore highly appreciated as they allow 
flexibility of the protein during the docking process. Different protein conformations (X-ray 
structures or taken from MD simulations) are selected and multiple docking runs are 
performed. As this approach is extremely costly, the more efficient method of ensemble 
docking should be used preferentially. Therefore an average receptor grid is generated and 
used for docking (Knegtel et al., 1997).  
A hybrid technique that is commonly used to encounter protein flexibility is the induced fit 
docking protocol of the Schrödinger Suite (Sherman et al., 2006). This method turns major 
attention on the ligand-induced conformational changes of the protein residues surrounding 
the binding site. Therefore, the ligand is docked into the rigid binding pocket, amino acid 
residues that are within a certain radius of the resulting poses are removed and rebuilt using 
the Schrödinger homology modeling program Prime. After energy minimization of the 
complex the ligand is redocked into the modified binding pocket.  
2.2.3 Scoring functions 
The application of a scoring function is important to assess the quality of ligand orientations 
in the binding pocket that resulted from docking experiments. Basically there are three areas 
of use for scoring functions. In order to understand the interaction between a defined 
molecule and the target protein the scoring function needs to be able to identify the true 
pose among the plethora of orientations, generated by the search algorithm. For lead 
optimization in particular a scoring function should correctly determine the affinity between 
the ligand and the protein. However, for virtual screening of large compound databases 
scoring should provide correct ranking. As there are still limitations regarding computer 
power, the right balance between accuracy and speed has to be chosen, which is strongly 
dependent on the field of application (reviewed in (Huang et al., 2010)). 
Force field based scoring functions use terms that describe the free energy of binding for 
evaluating binding poses. In that regard bond stretching, angle bending and dihedral 
angle forces for the ligand, but also non-bonded VDW and electrostatic interactions with 
the protein are calculated (Huang et al., 2006). Furthermore the accuracy of these methods 
depends on their treatment of the solvent. More accurate techniques, like thermodynamic 
integration or free energy pertubation, treat water molecules explicitly. As these are the 
most expensive affinity prediction methods, more simplified and computationally less 
expensive versions are linear interaction energy (LIE) models, where two additional 
empirical parameters can be used to reduce the number of simulations needed. On the 
other hand, MM/PBSA and MM/GBSA methods gain speed by using implicit solvent 
models.  
However all of these methods are still not applicable for virtual screening as they are 
computationally too expensive. 
Empirical scoring functions are therefore a fast alternative. They assess the quality of 
binding by a number of weighted terms that are derived by fitting data of complexes to 
known affinities (Bohm, 1994; Bohm, 1998). Numerous commonly used scoring functions 
belong to this group, including ChemScore (Eldridge et al., 1997) and X-Score (Wang et al., 
2002). Nevertheless, a disadvantage of this method would be the dependence on the training 
set, as complexes with binding affinity are essential. 
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Thus, knowledge-based scoring functions may be preferred in this regard. These scoring 
functions make use of the statistical occurrence of protein-ligand interactions of complex 
databases. In contrast to empirical functions they do not aim at reproducing binding-
affinities, but experimentally determined structures, wherefore a much larger training set 
can be used (Tanaka & Scheraga, 1976). Representatives of this group of scoring functions 
are among others ITScore (Huang & Zou, 2006; Huang & Zou, 2006) and DrugScore (Gohlke 
et al., 2000). A further development of the ITScore by Zou et al. ITScore/SE managed to 
include solvation and entropic effects into the scoring function (Huang & Zou, 2008), which 
lead to a strong increase in scoring accuracy. 
As the choice of the scoring function strongly depends on the research query, the 
combination of several functions, so-called consensus scoring, has been suggested 
(Charifson et al., 1999).  
2.3 Molecular dynamics 
It is obvious that the mechanism of action by which certain nutrients or drugs are 
translocated by a transporter implicates the protein to be flexible. In order to be able to allow 
for a sufficient comprehension of the dynamics of the transport protein, we can not only rely 
on experimental techniques. In addition, biomolecular simulations can provide a detailed 
description of particles in motion as a function of time. Thus, they are an important tool for 
understanding the physical basis of the structure and function of proteins, and biological 
macromolecules in general. However, experimental validation should always serve to test 
the accuracy of the calculated results and also to provide a basis for improving the 
methodology (Karplus & McCammon, 2002). 
It is almost 35 years ago, since for the first time McCommon, Gelin and Karplus have 
studied the dynamics of the pancreatic trypsin inhibitor by solving the equations of motion 
for the atoms with an empirical potential energy function (McCammon et al., 1977). In this 
very beginning of Molecular Dynamics simulations, the calculations were still restricted to 
the picosecond timescale. However, according to Moore’s Law computer power is doubling 
approximately every two years (Moore, 1965). Thus, MD simulations of biomolecules now 
are able to stretch up to microseconds. For the study of biological relevant phenomena like 
enzyme catalysis or even protein folding, MD has become a standard tool – always 
complementary to experimental techniques. 
2.3.1 Theory, fields of application, strengths and limitations of MD simulations 
By integrating the Newtonian Equations of Motion, Molecular Dynamics simulations are 
able to describe the behavior of particles in a certain system within the observed period of 
time. The interaction of the atoms is described by the potential energy function of the given 
force field [e.g. Amber (Cornell et al., 1995), CHARMM (Brooks et al., 1983), GROMOS (Scott 
et al., 1999), OPLS (Jorgensen & Rives, 1988)]. Nowadays, there is an ongoing effort to 
ameliorate these parameters in a need for models being as less artificial as possible. 
The field of application of biomolecular simulations is manifold. It reaches from validation 
and optimization of previously built homology models, refinement of crystal structures,  
to the prediction of protein-ligand, and protein-protein interactions, to the study of 
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functional properties of biological systems at the atomic level (e.g. protein-folding, 
destabilization or structural change of a protein upon mutation), to even de novo design of 
proteins (Park et al., 2005). 
Despite obvious drawbacks of classical MD simulations, which include limitations in time 
scales that can be studied but also certain inaccuracies of the force field, for instance with 
respect to polarization effects, the ability of bringing molecular structures alive also allows 
the researcher to sample the conformational space. This is especially interesting in ligand-
docking applications. On one hand, various extracted snapshots from a previously MD-
equilibrated protein-ligand complex may serve in order to perform an ensemble docking 
which is said to outperform docking into only one sample structure (Knegtel et al., 1997). 
Secondly, MD may also be used in order to refine certain poses and study the ligand-protein 
interactions on a molecular basis as a function of time. 
2.3.2 Simulations in a membrane 
The setup of a simulation system, which includes a protein embedded into a lipid bilayer 
requires additional efforts in comparison to a system with a soluble protein. There are 
different choices the researcher has to make regarding to the nature of the phospholipid 
bilayer used, the temperature at which the simulations should be performed (this also 
depends on the nature of the bilayer), the force field, the water model (e.g. SPC, SPC/E, 
TIP3P, TIP4P, TIP5P; this also depends on the choice of the force field), and many more. 
One of the most challenging parts is the correct parameterization of the ligands. According 
to the force field that has been selected there are diverging approaches, ranging from a pure 
manual assignment of partial charges and force constants, to the use of scientific software 
like Gaussian (www.gaussian.com), to an automated procedure by taking advantage of 
platforms such as the Automated Topology Builder and Repository (Malde et al., 2011). 
However, it has to be stated clearly that a manual inspection and refinement of suchlike 
obtained topologies will always be needed. 
Membrane proteins should be placed in a bilayer which is as similar as possible to its native 
environment. There is a diverse spectrum of phosphlipid bilayers available – differing 
mainly in the charges of their polar head groups, lengths and saturation of their acyl chains. 
If lipids play key roles in the proteins function, different combinations of lipids will 
probably better represent the in vivo conditions. It should always be kept in mind that in 
order to simulate the membrane in a liquid-crystalline state the temperature of the 
simulation needs to be above the melting temperature of the chosen lipids (phase-transition 
temperature). 
The protocols for setting up MD simulations of membrane proteins are manifold. In any 
case, however, one needs a pre-equilibrated bilayer, which can be retrieved from different 
groups around the world (e.g. Peter Tieleman, Scott Feller, Helmut Heller, Mikko 
Karttunen) or an individual bilayer may be generated and equilibrated with regard to the 
respective size and nature of the protein to be studied. 
When it comes to the insertion of the respective protein into the pre-equilibrated bilayer, 
again no standard protocol has been established up to now. In any case, it is of utmost 
importance to obtain a system with a tightly packed bilayer around the protein, so that the 
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consecutive equilibration time for the membrane can be kept quite short. Protocols like 
inflategro (Kandt et al., July 2009; Kandt et al., 2007) or g_membed (Wolf et al., 2010) seem 
most suitable. Whereas, inflategro inflates the lipid bilayer, insert the protein and then 
deflate the lipid bilayer again, g_membed does it the other way around. It grows a protein 
into an already hydrated and equilibrated lipid bilayer during a short MD simulation. A 
special case of insertion procedure certainly is the use of coarse-grained simulations. Here 
the lipids are able to self-assemble around the protein. However, as this type of simulations 
use a very simplified description of interactions, for a lot of investigations the relevant 
information might not be captured. 
An idea of a general protocol for the set up of a MD simulation can be found here: 
1. Choose a force field for which you have parameters for the protein and lipids.   
2. Insert the protein into the membrane.  
3. Solvate the system and add ions to neutralize excess charges and adjust the final ion 
concentration  
4. Energy minimize. 
5. Let the membrane adjust to the protein. Typically run MD for ~5-10ns with restraints on 
all protein heavy atoms. 
6. Equilibrate without restraints (gradually release the protein). 
7. Run production MD. 
8. Analysis. 
As seen from this overview, after the insertion of the membrane protein it is inevitable to 
properly equilibrate the lipid bilayer again. This is done by restraining the protein (plus 
eventually existing ligands conserved water molecules, ions, and cofactors) during a MD run 
where the membrane is able to adjust to the protein. Subsequently, the whole system has to 
undergo an extensive equilibration procedure. The end point of the equilibration phase and 
simultaneous starting point for the MD production run can be determined mainly by 
evaluation of system parameters (e.g. total energy, temperature) and parameters concerning 
the protein (e.g. backbone root mean square deviation). A production run for membrane 
proteins typically resides somewhere in between 50 ns and hundreds of nanoseconds. 
2.3.3 Enhanced sampling techniques 
As already mentioned in chapter 2.3.1, classical MD simulations are confronted with their 
limitations in time scales. The limiting factor is the maximum timestep that can be used for 
the integration, determined by the fastest motion in the system (e.g. bond vibrations). 
Thus, it is not able to study ‘slow’ biological processes without taking advantage of 
enhanced sampling techniques. This includes of course always a method, which works at 
the expense of fidelity. 
As outlined in an excellent review of Christen and van Gunsteren (Christen & van 
Gunsteren, 2008) we have to distinguish three different types of search and sampling 
enhancement techniques: deformation or smoothening of the potential energy surface (e.g. 
Coarse-graining the model by reducation of the number of interaction sites), scaling of 
system parameters (e.g. simulated temperature annealing), and multi-copy searching and 
sampling (e.g. replica-exchange algorithm). 
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If we want to study membrane proteins and especially their interactions with ligands 
sampling along transition pathways will be needed. Such pathways are often characterized 
by high-energy barriers separating meta-stable states along the ligand/substrate transition. 
Here, methods like pulling or steered MD (SMD) and targeted MD (TMD) may be used in 
order to drive the sampling to a specific direction. In the SMD approach external forces are 
applied on certain atoms in order to accelerate processes that are otherwise too slow to 
model (Isralewitz et al., 2001). Subsequently, the potential of mean force required to induce 
the transition can be used to estimate free energy barriers. This method is well established 
and has been used in many applications (Isralewitz et al., 2001; Lu & Schulten, 1999). 
In the TMD method, the reaction coordinate is defined by a single mass-weighted root 
mean-square ‘target distance’ between a known initial structure and a fixed final (target) 
structure. By gradually reducing the constrained target distance to zero, the system is driven 
from the reactant to product state without explicitly defining the reaction pathway (Schlitter 
et al., 1994). 
3. Recent developments in transporter research – Examples 
3.1 ABC Transporters and multidrug resistance 
ABC (ATP binding cassette) transporters are ubiquitous proteins that are expressed by 
prokaryotic and eukaryotic organisms. About 50 human ABC transporters are known, 
which are divided into seven different subfamilies, designated A-G.  
Depending on ABC subfamily substrates include among others drugs, lipids, bile salts, 
peptides, ions and amino acids. Additionally some ABC proteins are known for transporting 
a broad variety of chemically diverse molecules, which are therefore referred as multidrug 
transporters. Besides their physiologically important protecting function of exporting 
xenotoxins, these efflux pumps affect pharmacokinetic profiles of many drugs. Furthermore 
the acquisition of multidrug resistance (MDR) can often be traced back to elevated 
expression of multidrug transporters in the affected cells.  
The three ABC transporters mostly associated with MDR are P-glycoprotein (P-gp, ABCB1), 
multidrug resistance protein 1 (MRP1, ABCC1) and breast cancer resistance protein (BCRP, 
ABCG2). 
P-gp is encoded by the mdr1 gene and is expressed in epithelial cells of the blood brain 
barrier, liver, kidney and intestine, where it is located at the apical side of the membrane 
(Szakacs et al., 2008) (Fig. 1).  
The cells of the blood brain barrier (BBB) are closely linked by tight junctions, which 
practically prevent hydrophilic molecules to diffuse between the cells into the central 
nervous system (CNS). However, as hydrophobic substances might diffuse through the 
membrane, it is the role of P-gp to keep those out as well (Neuhaus & Noe, 2009).  
The protecting function of P-gp at the BBB has been observed with mdr1 knock-out mice 
and the dog breed collie, which naturally lacks functional P-gp because of a mutated  
mdr1 gene. Collies are extremely susceptible to neurotoxic drugs and thus show dramatic 
adverse reactions after treatment with the antiparasitic drug ivermectin (Mealey et  
al., 2001).  
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This detoxifying role of P-gp can be observed at other barriers as well (e.g. the fetal-maternal 
barrier), but also in faster clearance of administered drugs as it exports substrates form the 
hepatocytes into the bile, and from the intestinal epithelium into the intestinal lumen 
(Schinkel & Jonker, 2003). 
 
Fig. 1. Localization of the three most important multidrug-transporters. 
However, in drug research P-gp poses a large problem, since it highly influences 
pharmacokinetic properties of drugs. Because of the efflux behavior in the intestinal 
epithelium the oral bioavailability of drugs is hindered. There are a number of compounds 
that are able to modulate P-gp activity, which results in modified P-gp concentrations in the 
target tissue. As a consequence this can lead to adverse drug-drug interactions, when 
therapeutics are administered at the same time. Furthermore, elevated expression of P-gp, 
(as it is the case in cancer cells), is one major reason for the acquisition of MDR. One way to 
overcome these negative effects associated with P-gp activity would be the development of 
P-gp inhibitors that should restore sensitivity to therapeutics. Already 30 years ago, the 
reversal of resistance against the vinca alkaloids vincristine and vinblastine by the calcium-
channel blocker verapamil was identified (Tsuruo et al., 1981). However, since then no 
inhibitor reached the market so far. This can be explained by its important physiological 
functions, rendering them rather antitargets than targets (Ecker & Chiba, 2009).  
Another ABC transporter that is highly associated with MDR belongs to the ABCC 
subfamily. MRP1/ABCC1 is located at the basolateral membrane of epithelial cells of the 
lung, kidney and the intestine (Fig. 1).  
Although the substrate specificity of MRP1 shows some overlap with P-gp especially in 
terms of hydrophobic substances, MRP1 preferably binds to anionic substances in contrast 
to the positive charged substrates of P-gp (Borst & Elferink, 2002). Furthermore MRP1 is 
known for the export of hydrophilic substances as glutathione (GSH) conjugates. Therefore 
it is not only responsible for preventing xenotoxins entering the cell, but MRP1 also effluxes 
toxic metabolic compounds, which is highly important for faster clearance.  
The role of MRP1 in the acquisition of MDR has particular impact on non-small cell lung 
carcinoma, a very aggressive cancer type, where high concentrations of MRP1 could be 
detected in the cancer cells.  
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The development of MRP1 specific inhibitors faces immense problems as MRP1 substrates 
and inhibitors show anionic properties, which lack good cell penetration properties 
(Schinkel & Jonker, 2003). 
In 1998 Doyle et al. identified another ABC transporter that conferred resistance to the 
anthracenedione mitoxantrone, which is a poor substrate for P-gp and MRP1 (Doyle et al., 
1998). BCRP belongs to the G or white subfamily of ABC transporters and received the name 
BCRP because of its isolation from a breast cancer cell line.   
As P-gp, BCRP is located at the apical membrane of epithelial cells in the intestine, kidney 
and placenta (Schinkel & Jonker, 2003) (Fig. 1). Regarding substrate profiles, BCRP shows 
some overlap with P-gp and MRP1 but does not confer resistance to taxols, cis-platin and 
verapamil, or vinca alkaloids and anthracyclines. On the other hand, BCRP is known for 
transporting positively and negatively charged drugs (Sharom, 2008).  
A specific inhibitor of BCRP is the tremorgenic mycotoxin fumitremorgin C (FTC). FTC 
blocked mitoxantrone transport by BCRP without affecting P-gp or MRP1-mediated drug 
resistance (Rabindran et al., 2000). However, due to neurotoxic effects in vivo application is 
still not possible. 
3.1.1 Structure of ABC transporters 
The minimal functional unit of an ABC transporter consists of two (pseudo)-symmetric 
halves that comprise a transmembrane (TM) and a nucleotide binding domain (NBD) (Fig. 
2). In the case of P-gp and most other eukaryotic ABC transporters, these subdomains are 
fused to one polypeptide chain. On the contrary BCRP is a so-called half-transporter (Fig. 2). 
Half-transporters express each protein half separately and thus need to homo-dimerize to 
yield functional full transporters. 
 
Fig. 2. Topology of the three most relevant multidrug transporters. 
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The NBDs are responsible for the binding and hydrolysis of ATP, which is needed for the 
active transport of substrates. On each NBD sequence the characteristic ABC domain 
consisting of the Walker A and B region, as well as the “signature” or C motif, can be found 
(Fig. 3). One ATP molecule is supposed to be sandwiched between the Walker A and B of 
one NBD and the C motif of the other NBD (Fig. 3). As they are highly conserved, the NBDs 
show large sequence identity among ABC transporters. 
 
Fig. 3. Position of one ATP molecule in one nucleotide binding domain.  
However, substrate binding and transport occurs at the TMDs. Each TMD consists of six TM 
helices, although this number varies between ABC transporters. The TMDs are much less 
conserved which leads to a large diversity in substrate profiles among ABC transporters.  
During drug transport P-gp and its homologues undergo large conformational changes, 
converting an open-inward drug-binding state into an open-outward drug-releasing state 
(Rosenberg et al., 2001). This assumption was confirmed by cryo-electron microscopy and 
biochemical experiments, where P-gp was trapped in different states of the catalytic cycle 
(using the non-hydrolysable ATP analog AMP-PNP and ADP-Vi). The detailed mechanism 
of the energy driven drug transport, rendering the high-affinity into a low-affinity binding 
site, is currently hypothesized in two different ways and has been extensively reviewed in 
(Seeger & van Veen, 2009). 
3.1.2 Homology modeling of P-gp 
As already described in the introduction of this chapter, entries in the protein data bank 
(PDB) raise exponentially, but the structure determination of membrane proteins is still 
problematic and only relatively few structures have been resolved up to now. Thus, 
homology modeling is essential for performing docking or MD studies on most of the ABC 
transporters. 
In 2001 the publication of X-ray structures of E. coli MsbA (PDB code: 1JSQ, resolution: 
4.5Å), a lipid A transporter, raised a lot of interest in the ABC-transporter community 
(Chang & Roth, 2001).  
The lipid flippase MsbA is an ABC protein that is responsible for the transport for lipid A 
and lipopolysaccharide (LPS). A non-functional MsbA leads to accumulation of 
lipopolysaccharide and phospholipids in the inner membrane of gram-negative bacteria.  
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According to the X-ray structure published in 2001 the association of the two TMDs was 
interpreted as a chamber that provides alternating access for potential ligands during the 
catalytic cycle. The theory of MsbA switching between different conformations was 
confirmed by the subsequent publications of the X-ray structures of Vibrio cholerae MsbA in 
2003 (PDB code: 1PF4, resolution: 3.80Å) (Chang, 2003) and of Salmonella typhimurium 
MsbA in complex with ADP·Vi  (PDB code: 1Z2R, resolution: 4.20Å) (Reyes & Chang, 2005). 
The former presents the apo protein in a closed state, while the latter captures the 
Protein/ADP·Vi complex in the posthydrolytic state.  
At this time these structures were the only source for structure-based design on MsbA and 
its homologues. Numerous ABCB1 homology models were generated relying on these 
MsbA templates (Pleban et al., 2005; Seigneuret & Garnier-Suillerot, 2003; Shilling et al., 
2003; Stenham et al., 2003; Vandevuer et al., 2006).  
However, with the publication of the X-ray structure of the Staphylococcus aureus transporter 
Sav1866, an MsbA homologue (Dawson & Locher, 2006), the previous MsbA and two 
additional EmrE structures had to be retracted (Chang et al., 2006). According to Chang, an 
error in the in-house software that should process the crystallographic data resulted in a sign 
change and therefore to a momentous misinterpretation of the data (Matthews, 2007). This 
incident became the center of numerous discussions, often referred to as the 
“pentaretraction” (Davis et al., 2008; Penders et al., 2007). In contrast to the retracted MsbA 
models, the architecture of Sav1866 shows a helix arrangement that is analogous to domain 
swapping in other enzymes. Thus, TM helices of one TMD are in close contact with the 
opposite NBD via so-called coupling helices. 
One year later, in 2007, Ward et al. published the corrected MsbA structures (Ward et al., 
2007), which are in agreement with the SAV1866 architecture.  
As SAV1866 (PDB code: 2HYD, resolution: 3.00Å) is one of the best resolved ABC exporters 
it has been often used as template for further modeling studies. In addition, this structure 
also fulfills most of the structural restraints that were obtained by cross-linking studies. 
However SAV1866 was crystallized in the nucleotide-bound conformation, which 
represents the ligand-releasing state of the protein. Thus the suitability of this template for 
docking studies can be questioned. In this respect Stockner et al. generated a data-driven 
homology model on the basis of SAV1866 that should represent the ligand-binding state of 
the protein by applying structural restraints in TM helices 6 and 12 obtained by cross-
linking data on the model (Stockner et al., 2009). 
The corrected MsbA coordinates cover different catalytic states, including a nucleotide-free 
ligand-binding conformation. Unfortunately these structures are resolved at resolutions far 
from being suitable for docking experiments, with some templates only represented by C 
atoms. Models on basis of the MsbA structures were therefore mainly used for exploring the 
conformational changes during the catalytic cycle.  
With the publication of murine P-gp in March 2009 the first X-ray structure of a eukaryotic 
ABC exporter was available (Aller et al., 2009) (PDB code: 3G5U, resolution: 3.8Å). Two 
additionally published structures that include co-crystallized enantiomeric cyclic peptide 
inhibitors (CPPIs; QZ59-RRR and QZ59-SSS) highlight the binding-competence of these 
conformations and thus their great value for further docking studies. Furthermore the high 
sequence identity of 87% with human P-gp highly facilitates the modeling process. 
www.intechopen.com
 Molecular Modeling and Simulation of Membrane Transport Proteins 
 
389 
3.1.3 Docking and MD studies  
The definition of a binding site is an essential preparation step for docking studies. 
Regarding P-gp and other ABC transporters, we face the problem that hardly any binding 
sites for known P-gp ligands have been identified unambiguously. So far, it has been 
assumed that there is a large binding cavity in the transmembrane region (Loo & Clarke, 
1999), which comprises distinct active sites. Furthermore, cysteine-scanning mutagenesis 
studies showed that the protein is able to bind at least two different molecules 
simultaneously (Loo et al., 2003). By using biochemical techniques a more detailed 
characterization of concrete binding sites for distinct substrates was possible (extensively 
reviewed in (Crowley et al., 2010; Loo & Clarke, 2008; Seeger & van Veen, 2009)). This led to 
the characterization of the interaction regions of Rhodamine 123 and Hoechst 33342, named 
R- and the H- site (Loo & Clarke, 2002; Qu & Sharom, 2002), together with a regulatory site, 
which binds prazosin/progesterone (Shapiro et al., 1999). Furthermore, the release of the P-
gp/CPPI-complexes presented another step forward in elucidating drug/P-gp interactions. 
Since the co-crystallized enantiomers showed distinct binding patterns, this information 
raised the assumption of stereoselectivity of P-gp in its ligand binding quality (Aller et al., 
2009). Stereoselectivity has also been shown for flupentixol (Dey et al., 1999) and 
propafenone derivatives (Jabeen et al., 2011). On the other hand there are also ample reports 
on equal activity of enantiomeres. Thus, as for niguldipine and verapamil both enantiomers 
showed equivalent activities (Hollt et al., 1992; Luurtsema et al., 2003), the distomers with 
respect to cardiovascular activity were used for clinical studies.  
As the resolution of the hitherto available templates used for constructing protein homology 
models is quite low, only very few docking studies have been conducted so far. Shortly after 
the publication of mouse P-gp, Pajeva et al. docked quinazolinones into a homology model 
of human P-gp based on the murine homologue, which is in complex with the cyclopeptide 
SSS-QZ59 (Pajeva et al., 2009). The binding site they used was defined by the co-crystallized 
ligands and was extended by 14Å. The results suggested interaction with TM helices 5, 6 
and 11 and were further confirmed by a pharmacophore model.  
Becker et al. performed docking studies of the P-glycoprotein modulators colchicine, 
rhodamine B, verapamil and vinblastine into a homology model based on the nucleotide-
free corrected MsbA structure (Becker et al., 2009). The resultant poses predicted that all 
ligands were able to interact with residues that were experimentally identified as important 
for ligand binding, strongly involving TM helices 5, 6, 7, 11 and 12. However, none of the 
drugs was able to contact every identified residue, which favors the hypothesis of distinct 
interactions sites forming one binding cavity.  
Recently Dolghih et al. published a docking approach that was able to discriminate between 
known P-gp binders and non-binding metabolites (Dolghih et al., 2011). In this study there 
was a major interest in considering the high flexibility of P-gp. Therefore the induced fit 
protocol of the Schrödinger Suite was applied (Sherman et al., 2006). However, the 
discrimination between binders and non-binders can be more efficiently performed on basis 
of physicochemical properties than different binding mechanisms.  
In our group, docking into a homology model based on mouse P-gp was used for explaining 
the stereoselective P-gp modulating activity of tricyclic benzopyranooxazines (Jabeen et al., 
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2011). Besides from activity differences, compounds with 4aS,10bR configuration showed a 
clear logP-activity correlation (r2=0.96), which was not the case for the 4aR,10bS series. This 
characteristic could be partly explained by the received binding hypotheses. The analysis of 
the docking poses by agglomerative hierarchical clustering resulted in distinct clusters for 
the different diastereomers. Therefore it has been hypothesized, that activity differences of 
the diastereomers is due to their different binding modes in the P-gp binding cavity. In 
addition, molecules with 4aR,10bS chirality were found close to the entry path of the 
protein, wherefore activity is primarily affected by the molecules’ partition coefficient. On 
the other hand compounds of the 4aS,10bR series also showed docking poses at an active 
site in the binding pocket of P-gp, thus suggesting that the activity is dependent on multiple 
factors.  
Furthermore, we were able to propose reliable binding hypotheses of propafenone analogs 
in P-gp by applying a knowledge driven docking protocol (Klepsch et al., 2011). Based on 
our extensive data from SAR studies on propafenones (Ecker et al., 2008; Pleban et al., 2005), 
we selected a small set of compounds for docking into a homology model based on mouse 
P-gp. As propafenone analogs show a clear SAR we assumed a similar binding mode of the 
docked propafenone derivatives. In that sense the resultant docking poses were clustered 
according the RMSD of their common scaffold. The clusters were prioritized according a 
combination of SAR data and protein-ligand interaction fingerprint information. With this 
protocol a high number of docking poses could be reduced to two reliable binding modes. 
Key interactions formed by these two clusters were formed with amino acids of TM helices 
5, 6, 7 and 12 which were shown previously to be involved in ligand binding (Loo & Clarke, 
2008; Seeger & van Veen, 2009).  
In contrast to the compounds investigated above steroidal compounds are assumed to bind 
to the NBD rather than the TMDs. Several docking studies could show ATP-like binding of 
flavonoids, flavones and chalcones at the ATP-binding site, which is extensively reviewed in 
(Klepsch et al., 2010).   
Regarding P-gp’s high flexibility MD simulation represents a convenient technique to 
consider structural changes of the protein. Unfortunately, a number of MD studies were 
conducted relying on homology models based on the retracted MsbA X-ray structures 
(Campbell et al., 2003; Omote & Al-Shawi, 2006; Vandevuer et al., 2006) and are therefore 
partly no longer valid. 
By now MD methods were mainly used for functional investigations of the protein. In order 
to determine the mechanisms of ATP hydrolysis numerous studies were conducted on 
isolated NBDs (Campbell & Sansom, 2005; Jones & George, 2007; Jones & George, 2009; 
Newstead et al., 2009; Wen & Tajkhorshid, 2008), as this comprises the sequence motives 
essential for ATP-binding. However, recently also studies considering the behaviour of the 
whole protein upon ATP hydrolysis were published (Becker et al., 2010; Gyimesi et al., 2011; 
Oliveira et al., 2011). All of those studies relied on the SAV1866 crystal structure, which 
represents the ligand-releasing and therefore open-outward state of the protein.  
While Oliveira et al. (Oliveira et al., 2011) were able to show that replacing both ATP 
molecules in the NBDs by ADP structural changes in the protein occurred, Gyimesi et al. 
(Gyimesi et al., 2011) observed structural rearrangements already by exchanging one ATP 
molecule. This could be of great relevance for heterodimeric ABC proteins like P-gp, where 
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an asymmetric ATP hydrolysis might be possible. In addition movements in TM helices 3 
and 6 could be identified, which is in agreement with MD studies conducted by Becker et al. 
(Becker et al., 2010). Both groups observed closure of the TM domains after ATP hydrolysis.  
The investigation of the drug-binding open-inside conformation of P-gp by MD simulation 
still faces numerous problems, due to instability of the mouse P-gp structure. In that sense 
the validity of this model is somewhat doubted (Gyimesi et al., 2011; Loo et al., 2010). 
3.2 Neurotransmitter transporters 
3.2.1 Biological background of the SLC-6 family 
The concerted release and reuptake of transmitter substances is a basic principle of proper 
signal transduction in the nerve cells. In order to terminate a synaptic signal after neural 
firing, transporter proteins have to remove about 105-fold of basal concentrations (Chen et 
al., 2004; Gouaux, 2009). The transporters practically have to act as selective molecular 
vacuum cleaners to deal with such huge loads of neurotransmitters in order to re-establish 
pre-signaling conditions within milliseconds. A major ion gradient serves as driving force 
and patron for the protein class: the Neurotransmitter:Sodium Symporters (NSS).  
Synonymously called the solute carrier 6 family (SLC-6), NSS members include the sodium- 
and chloride-dependent transporters for GABA, dopamine, serotonin, norepinephrine and 
glycine, but also just sodium-dependent transporters of amino acids. Thus, the protein 
family is of particular medical importance, as many CNS diseases like depression, anxiety or 
epilepsy can be targeted by inhibiting transporters (Iversen, 1971). 
They share a basic scaffold consisting of 12 transmembrane regions (TMs), segments 1-5 and 
6-10 forming two pseudosymmetric domains housing the substrate and ion binding sites in 
partially unwound regions half-way across the membrane (Kanner & Zomot, 2008). 
The crystal structure of LeuT, a bacterial orthologue of the eukaryotic NSS members, 
became available in an occluded state conformation in 2005 and in the open to out 
orientation in 2008 (Singh et al., 2008; Yamashita et al., 2005), thus revealing first detailed 
insights into the binding site topology. Furthermore, very recently a double mutant 
stabilized in an inward-open conformation was published (Krishnamurthy & Gouaux, 
2012). These crystallographic snapshots fortify the so-called alternating access model for 
neurotransmitter membrane transport (Jardetzky, 1966). Various attempts have been made 
to clarify the exact molecular transport mechanism (Forrest et al., 2008; Shi et al., 2008), yet 
many questions remain unanswered. Concerning the quaternary structure, it is generally 
assumed that neurotransmitter:sodium symporters form constitutive oligomers (Forrest et 
al., 2008; Sitte et al., 2004). Despite a comparably poor average overall sequence identity 
between eu- and prokaryotic SLC-6 members of slightly above 20%, these structures paved 
the way to comparative modeling studies. Predominantly the monoamine transporters 
DAT, NET and SERT, but also GAT, have been modeled and studied extensively. For a 
comprehensive summary of the state of knowledge about the SLC-6 family, the reader is 
referred to the recent review by Kristensen et al. (Kristensen et al., 2011). 
3.2.2 Examples of studies on the hSERT 
As mentioned earlier, especially when dealing with low template-target sequence identity, a 
very careful sequence alignment including all possible experimental knowledge is crucial 
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for the construction of reliable homology models. For the main members of the SLC-6 family 
a lot of effort has been put into this work, resulting in the comprehensive alignment of NSS 
sequences with the LeuT published by Beuming et al. in 2006 (Beuming et al., 2006). Since 
then, some new structural insights into the protein class have been gained leading to slightly 
altered regions, but still the alignments can be considered a good starting point for 
experiments with NSS models. In the case of the hSERT, the recent work of Sarker et al. 
(Sarker et al., 2010) provides a good example for the cumulative value of combining 
molecular modeling methods with mutagenesis experiments in order to verify in silico 
elaborated hypotheses. For investigating the binding mode of tricyclic antidepressants 
(TCAs) in the serotonin transporter, comparative modeling marked the starting point for 
subsequent studies. Using the Beuming alignment, homology models of hSERT were built 
based on the previously mentioned high-resolution open-to-out structure of the LeuT 
published in 2008 (PDB code 3F3A). Subsequent docking studies of imipramine resulted in 
three pose clusters of potential binding modes, showing interactions to previously reported 
key residues (Andersen et al., 2009; Chen & Rudnick, 2000; White et al., 2006). A diagnostic 
Y95F mutation, a candidate residue for hydrogen bonding with the imipramine 
diaminopropyl moiety, significantly decreased imipramine affinity without affecting 
serotonin binding, ruling out one cluster. Further uptake and docking assays demonstrated 
that carbamazepine, structurally a truncated and slightly more rigid derivative of 
imipramine, was able to bind mutually non-exclusive with the substrate serotonin, whereas 
binding of its large-tailed relative is mutually exclusive. This led to the following 
conclusions: a) the tricyclic ring system of TCAs binds in an outer vestibule, and b) the basic 
side chain of imipramine points into the actual substrate binding site. 
 
Fig. 4. Molecular dynamics simulations of SERTThr-81 mutants reveal models favoring 
inward facing states. A, snapshot of wild type SERT after 16 ns of MD simulation. The Thr81 
side chain forms a stable H-bond with the backbone carbonyl of Tyr350 in IL3. B, snapshot 
of SERTT81A after 6 ns of MD simulation; the H-bond is not formed between Ala81 and 
Tyr350 during the course of the simulation. C, snapshot of SERTT81D after 6 ns of MD 
simulation; no H-bond is formed between Asp81 and Tyr350 during the course of the 
simulation. (taken from (Sucic et al., 2010)). 
As an example for a more functional study on the SERT, the work of Sucic et al. (Sucic et al., 
2010) can be mentioned. As it was analogously reported for the DAT (Guptaroy et al., 2009), 
the important role of a highly conserved phosphorylation site at the N-terminus of the 
transporter in mediating the action of amphetamines was studied. Amphetamines are said 
to induce substrate efflux, but the way they do so is not well understood. Sucic et al. 
reported that mutating the highly conserved N-terminal residue T81 (a candidate site for 
phosphorylation by protein kinase C), to alanine or aspartate leads to subsequent fail of the 
transporter to support amphetamine-induced efflux. As it was also confirmed by molecular 
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dynamics simulations of the wild type transporter, the in silico mutated SERTT81A and 
SERTT81D, the data suggested that by phosphorylation or in silico mutation of T81 the 
conformational equilibrium of the serotonin transport cycle alters towards the inward facing 
conformation. As seen in the MD studies, this happens due to a loss of a hydrogen bond 
network of T81 with Y350 in IL3 by these mutations. Furthermore, an increased distance 
between the C terminus (i.e. the most distal point of TM12) and the N terminus after in silico 
mutation was observed. This example nicely indicates how functional MD studies might aid 
in elucidating biological relevant phenomena. 
3.2.3 Studies on hGAT models 
The four Na+- and Cl--dependent GABA transporters, GAT-1-3 and BGT-1 (SLC6A1, A16, 
A11, A12), provide a similar percentage of sequence identity to the LeuT. The subtype 
showing the highest quantity in the CNS is GAT-1. It is also the best-investigated, and the 
only one currently targeted by a marketed drug, the second-line antiepileptic tiagabine 
(Gabitril®). Accordingly, systematic synthesis studies in order to discover even more 
selective compounds have been performed mainly on GAT-1. Nevertheless, other subtypes 
should not be ignored, as they may be the key to a less side-effect afflicted antiepileptic 
therapy, as tiagabine efficacy as anticonvulsant is limited, and its use was connected to 
several adverse effects like sedation, agitation, or even seizure induction.  Neuronal GABA 
reuptake, mainly done by GAT-1, leads to subsequent recycling of the transmitter substance. 
On the contrary, astroglial uptake of GABA leads to degradation, suggesting subtypes 
predominantly present in glia cells being an interesting target for enhancing overall GABA 
levels. For example, the lipophilic GABA analog EF-1502, characterized by GAT1 and GAT2 
(BGT-1) selectivity, showed synergistic anticonvulsant activity, when administered with 
tiagabine (Schousboe et al., 2004), although BGT1 levels in the CNS are about 1000-fold 
lower, and even a recent study with BGT-1 knockout mice did not show any change in 
seizure susceptibility (Lehre et al., 2011). 
In the search for potent selective non-GAT-1 inhibitors, GABA mimetic moieties (like R-
nipecotic acid in tiagabine, β-alanine or THPO [4,5,6,7-Tetrahydroisoxazolo(4,5-c)pyridin-3-
ol]) were systematically combined with large aromatic side chains, both in order to increase 
the affinity and to make the compounds blood-brain barrier permeable (Andersen et al., 
1993; Andersen et al., 1999; Clausen et al., 2005; Knutsen et al., 1999; Kragler et al., 2008). 
Unfortunately, up to now no truly selective tools for the evaluation of non-GAT-1 inhibition 
are available, although the GAT-1/BGT-1 inhibitor EF1502 and SNAP-5114, showing a 
certain GAT-2/GAT-3 selectivity, mark a good starting point (Madsen et al., 2010). Thus, 
further insights into the molecular basis of ligand binding are sought by the aid of in silico 
methods. 
GAT-1 has been subject of several comparative modeling studies. Initial studies 
predominantly aimed at clarifying the GABA binding mode in the occluded transporter 
state, which is quite well documented so far (Pallo et al., 2007; Wein & Wanner, 2009). 
Though, compounds with large aromatic tails cannot be accommodated in the occluded-
state active site, as the entrance to the binding pocket is barred by the two extracellular gate 
residues R69 and D451, as well as the F294 side chain, forming the binding site “roof”. In 
order to study tiagabine-like ligands, constructing open-to-out models seemed inevitable, as 
it was done by Skovstrup et al. (Skovstrup et al., 2010). Structures of both states were 
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modeled and refined exhaustively, as described in section 2.1. The combined use of docking 
and molecular dynamics simulation was chosen to investigate binding of GABA, its 
analogue (R)-nipecotic acid and the high active (R)-enantiomer of tiagabine. The results for 
GABA binding were in line with the earlier mentioned experiments. In case of tiagabine, 
MD simulations helped to distinguish between the cis- and trans- conformer, both being 
possible states due to the protonated state of tiagabine at physiological pH. During the MD, 
the trans- conformer immediately stirred away to the extracellular space, whereas the other 
one remained stable in the binding site. Summing up, GABA and (R)-tiagabine turned out 
having two different binding modes, sharing the orientation of the carboxy group towards 
one of the co-transported sodium ions as a common feature. 
For the other GAT subtypes, things are a bit more complicated. Looking at the residues 
corresponding to LeuT substrate binding site, just a few candidate residues differ 
significantly, being somehow unlikely to be fully responsible for subtype selective binding. 
So far, molecular modeling studies have been performed, but highly similar binding sites 
and the lack of selective ligand data limited their explanatory power (Pallo et al., 2009). 
Thus, a huge field of activity remains to be explored on the way to fully understand the 
differences between the GABA subtypes, in silico methods being a valuable tool for stepwise 
adding pieces of information to the big puzzle. 
4. Concluding remarks 
Membrane transport proteins are responsible for one of the most important processes in 
living cells: directed transport across barriers. They comprise about 30% of known 
proteomes and constitute about 50% of pharmacological targets. Although, due to 
difficulties in expression, purification and crystallization, only about 2% of the high 
resolution crystal structures in the Protein Data Bank (PDB) are transporters. Thus, 
computational methods have been utilized extensively to provide significant new insights 
into protein structure and function. Above all, molecular modeling and molecular dynamics 
(MD) simulations may deliver atomic level details to reveal the molecular basis of e.g. drug-
transporter interactions. As shown on basis of recent research examples, in silico methods in 
many cases can provide additional information to biological experiments, either 
underpinning pharmacological results or they may even lead to new insight, not being 
biologically accessible. 
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